Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients

1059Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults

Background. Previous studies have demonstrated the superior immunogenicity of high-dose inactivated influenza vaccine (IIV-HD) in older adults compared to standard-dose inactivated influenza vaccine (IIV-SD), as measured by hemagglutination inhibition (HAI) antibody titers against egg-propagated vaccine antigens. The 20122013 northern hemisphere influenza season was characterized by high H3N2 a...

530Disease Modulation in Older Adults Vaccinated with High-Dose Versus Standard-Dose Influenza Vaccine

Background. High-dose inactivated influenza vaccine (IIV-HD) induces higher antibody responses and provides improved protection against influenza illness compared to a standard-dose vaccine (IIV-SD) in older adults. We evaluated its impact on disease modulation. Methods. A multicenter, randomized, double-blind, active-controlled trial compared IIV-HD (60 μg of hemagglutinin [HA] per strain) to ...

A Randomized Trial of High-dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients

Comparison of Side Effects of the 2015–2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults ≥65 Years

BACKGROUND High-dose, inactivated, trivalent influenza vaccine (HD) is associated with higher rates of side effects than standard dose (SD) vaccine, which may represent a barrier to use. METHODS We surveyed subjects ≥65 years who received either HD or SD vaccine at the Minneapolis Veteran Affairs Health Care System clinics on October 27, 28, or 29, 2015. Research assistants conducted a 17-ite...

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors

Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 hospitalizations and 3,500 deaths annually, mostly occurring in adults ≥65 years old (seniors). A 32,000-participant, randomized controlled clinical trial (FIM12; Clinicaltrials.gov NCT01427309) showed that high-dose inactivated influenza vaccine (IIV-HD) is superior to standard-dose vaccine (SD)...